The story of Viagra and its parent , copyright, presents a complex picture for cautious investors. While the blockbuster drug initially produced enormous revenues , its patent has expired , leading to generic options flooding the landscape . This reduction in cost presents a real challenge for copyright and any fund considering a heavy position in